Peter Sikiric, the peptide's principal investigator, has stated: "BPC-157 has demonstrated a remarkable safety profile across hundreds of experimental applications, with no observed lethal dose in any tested species and consistent organ-protective effects rather than organ-damaging ones" 1
Similar collection parameters were used for the tilted dataset (7,372 movies), except for a reduction of AFIS to +/ 6 m, a single nominal defocus value of 2 m, and a + 30 stage tilt
Average weight loss after 48 weeks Highest dose: around 24% of the starting body weight Mid dose: around 23% Lower dose: around 17% Placebo (dummy injection): around 2% What does 24% actually mean
All protocols, dosages, and treatment insights referenced herein are based on published literature
Consider combination approaches Some researchers explore stacking additional compounds with their primary GLP-1 agonist